Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.35 |
| ▸ | RARB | P10826 | 3/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | RARA | P10276 | 1/20 | 0.31 |
| ▸ | RARG | P13631 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | HTR1D | P28221 | 1/20 | 0.31 |
| ▸ | HTR1B | P28222 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.30 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20102572 | 0.91 | RARB (0.37) | GPR3RARBFFAR1FFAR4S1PR1 | |
| SCHEMBL20111480 | 0.81 | GRM5 (0.36) | FFAR1FFAR4 | |
| SCHEMBL20111272 | 0.80 | FFAR1 (0.39) | FFAR1FFAR4 | |
| SCHEMBL10302770 | 0.78 | RARB (0.46) | GPR3RARBFFAR1FFAR4S1PR1 | |
| SCHEMBL20102542 | 0.78 | RARB (0.43) | GPR3RARBS1PR1HTR2ARARA | |
| SCHEMBL20102472 | 0.77 | RARB (0.38) | GPR3RARBHTR2ARARARARG | |
| SCHEMBL20102529 | 0.77 | RARB (0.38) | GPR3RARBHTR2ARARARARG | |
| SCHEMBL20102532 | 0.76 | HSD17B10 (0.39) | GPR3RARBFFAR1FFAR4HTR2A | |
| SCHEMBL20102435 | 0.76 | RARB (0.45) | RARBHTR2ARARARARG | |
| SCHEMBL20102594 | 0.76 | RARB (0.38) | GPR3RARBFFAR1FFAR4RARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180119009-A1 | LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-05-03 | — | — | US | disclosed |
| US-20160023999-A1 | PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180119009-A1 | LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | YBX1, PIEZO1, C1S | GPR3 983/4885RARB 1858/4885FFAR1 536/4885 |
| US-20160023999-A1 | PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME | SCN1A, GABARAPL1, NAA10 | GPR3 925/4885RARB 1945/4885FFAR1 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.